Search Results

You are looking at 211 - 220 of 868 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018

Gregory P. Kalemkerian, Billy W. Loo Jr, Wallace Akerley, Albert Attia, Michael Bassetti, Yanis Boumber, Roy Decker, M. Chris Dobelbower, Afshin Dowlati, Robert J. Downey, Charles Florsheim, Apar Kishor P. Ganti, John C. Grecula, Matthew A. Gubens, Christine L. Hann, James A. Hayman, Rebecca Suk Heist, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar A. Moran, Daniel Morgensztern, Saraswati Pokharel, David C. Portnoy, Deborah Rhodes, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Charles C. Williams Jr, Karin G. Hoffmann, and Miranda Hughes

(Subsequent) Systemic Therapy Although SCLC is very responsive to initial treatment, most patients experience relapse with relatively resistant disease. 26 – 28 Randomized phase III trials have demonstrated the benefit of single-agent topotecan orally or

Full access

Optimizing BTK Inhibition in Waldenström Macroglobulinemia

Shayna Sarosiek and Jorge J. Castillo

immunosuppression associated with chemoimmunotherapy, BTK inhibitor therapy should be considered in the frontline setting or in patients with relapsed disease who have not yet been exposed to BTK inhibitors. Figure 1 shows a proposed genomics-driven treatment

Full access

CLO24-060: Organomegalies as a Predictive Indicator of Leukemia Cutis in the Patients With Acute Myeloid Leukemia

Chalothorn Wannaphut, Chanakarn Kanitthamniyom, Penvadee Pattanaprichakul, Smith Kungwankiatichai, and Weerapat Owattanapanich

and relapse-free survival were assessed. Pathological tissues underwent re-evaluation to validate LC diagnoses. The study included 159 patients in a 2:1 ratio (106 non-LC and 53 LC). The LC group had a mean age of 54.3 ± 15.5 years and a female

Full access

YIA23-003: CD19-CAR T Cells Develop Exhaustion Epigenetic Programs During a Clinical Response

Caitlin Zebley, Charmaine C Brown, Tian Mi, Yiping Fan, Shanta Alli, Shannon Boi, Giovanni Galletti, Enrico Lugli, Deanna Langfitt, Jean-Yves Metais, Timothy Lockey, Michael Meagher, Brandon Triplett, Aimee Talleur, Stephen Gottschalk, and Ben Youngblood

to mount an in vivo recall response after relapse of antigen-positive disease or recovery of endogenous B cells. Conclusions: These observations support the conclusion that CD19-CAR T cells acquire stable epigenetic exhaustion programs that limit

Full access

Chronic Myelogenous Leukemia, Version 1.2015

Susan O’Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Peter Curtin, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Vishnu VB. Reddy, Neil P. Shah, B. Douglas Smith, David S. Snyder, Meir Wetzler, Kristina Gregory, and Hema Sundar

(hyper-CVAD) has been shown to be effective for the treatment of patients with lymphoid BP-CML. 93 , 94 In a study of 34 patients with lymphoid BP-CML or relapsed Ph+ ALL, the addition of dasatinib to hyper-CVAD resulted in an overall response rate of 91

Full access

Testicular Cancer

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Mark K. Buyyounouski, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Shilpa Gupta, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Timothy M. Kuzel, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Jue Wang, and Richard B. Wilder

useful in monitoring metastatic seminomas, because elevated marker levels is the early sign of relapse. LDH is a less-specific marker than AFP and β-HCG. AFP is a serum tumor marker produced by nonseminomatous cells (embryonal carcinoma, yolk-sac tumor

Full access

The NCCN 2021 Virtual Congress: Hematologic Malignancies

Robert W. Carlson

Lymphoma,” and “Updates in the Management of Early-Stage Diffuse Large B-Cell Lymphoma.” Additional sessions focused on updates in the management of relapsed/refractory mantle call lymphoma, optimizing therapy for relapsed/refractory diffuse large B

Full access

Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin Lymphoma

Hugo J.A. Adams and Thomas C. Kwee

interim FDG-PET results demonstrated markedly increased relapse rates in all available studies. 3 In patients with advanced-stage HL with positive interim FDG-PET results, treatment escalation has not proven to be beneficial, because studies showing

Full access


Plus Belinostat in Relapsed/Refractory non-Hodgkin Lymphoma Subtypes Charalambos Andreadis, MD, MSCE; UCSF Helen Diller Family Comprehensive Cancer Center: A Phase Ib Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab

Full access

The Role of Transplant in Multiple Myeloma

Matthew Mei and George Somlo

Intergroup Trial S9321 found no PFS or OS benefit with early ASCT, although most of the patients who experienced relapse while undergoing chemotherapy confirmed that delayed ASCT had an adverse effect on OS. 14 Tandem ASCT Tandem ASCT refers to a